First-line biologic or JAK inhibitor plus methotrexate: more remission in early RA

Design

Systematic review with pairwise and network meta-analysis of RCTs

Population

13,387 methotrexate-naive adults with early RA in 29 trials

Primary outcome

DAS28 remission at 6 months

Effect

b/tsDMARD + MTX vs MTX RR 1.62 (1.39 to 1.89)

This meta-analysis, published in Rheumatology in September, pooled 29 randomised trials of 13,387 methotrexate-naive adults with early rheumatoid arthritis, comparing initial biologic or targeted synthetic DMARDs, with or without methotrexate, against methotrexate alone.

Adding a b/tsDMARD to methotrexate increased DAS28 remission at 6 months (RR 1.62, 95% CI 1.39 to 1.89), 3 months (RR 1.95) and 12 months (RR 1.54), with gains in CDAI remission and ACR50 too. Every class combined with methotrexate outperformed methotrexate alone in network analysis. Benefit was larger where baseline disease activity was high and more patients were rheumatoid factor positive. As monotherapy, b/tsDMARDs beat methotrexate overall (RR 1.81 at 6 months), but at class level only tocilizumab and JAK inhibitors were significantly better.

Most guidelines start with methotrexate and escalate. This analysis quantifies what is lost by waiting, particularly in high-activity, seropositive disease. It measures remission, not long-term damage or safety, and cost is often decisive. It supports considering first-line combination therapy in poor-prognosis patients rather than for all.

• Consider starting a biologic or JAK inhibitor with methotrexate in early RA with high disease activity and seropositivity.
• Use methotrexate as the anchor drug; combinations outperformed monotherapy for most classes.
• If methotrexate cannot be used, tocilizumab or a JAK inhibitor were the monotherapies that beat methotrexate.
• Apply JAK inhibitor class precautions for older patients and those with cardiovascular or thrombotic risk.

Why it matters

It puts a number on the remission lost by the standard step-up approach in high-risk early RA.

Don't overread it

Remission is the outcome; the analysis does not address long-term structural outcomes, safety or cost-effectiveness.

The statistics, in plain English

A risk ratio of 1.62 means about 60% more patients reached remission at 6 months with combination therapy. If 25 in 100 reach remission on methotrexate alone, about 40 in 100 would with combination therapy.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.